Compare MEDP & ARCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MEDP | ARCC |
|---|---|---|
| Founded | 1992 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.4B | 13.6B |
| IPO Year | 2016 | 2004 |
| Metric | MEDP | ARCC |
|---|---|---|
| Price | $585.01 | $19.62 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 12 | 11 |
| Target Price | ★ $473.17 | $21.36 |
| AVG Volume (30 Days) | 370.2K | ★ 4.5M |
| Earning Date | 04-22-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 10.28% |
| EPS Growth | ★ 20.98 | N/A |
| EPS | ★ 8.53 | 0.13 |
| Revenue | N/A | N/A |
| Revenue This Year | $13.19 | $5.77 |
| Revenue Next Year | $7.75 | $2.29 |
| P/E Ratio | ★ $68.90 | $148.62 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $373.00 | $17.40 |
| 52 Week High | $677.90 | $22.76 |
| Indicator | MEDP | ARCC |
|---|---|---|
| Relative Strength Index (RSI) | 63.66 | 61.40 |
| Support Level | $568.34 | $19.38 |
| Resistance Level | $621.43 | $20.69 |
| Average True Range (ATR) | 21.73 | 0.31 |
| MACD | -0.91 | 0.06 |
| Stochastic Oscillator | 44.99 | 79.53 |
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
Ares Capital Corp is a United States-based closed-ended specialty finance company. Its investment objective is to generate both current income and capital appreciation through debt and equity investments. The company focuses on investing in first lien senior secured loans (including unitranche loans, which are loans that combine both senior and subordinated debt, generally in a first lien position) and second lien senior secured loans. In addition to senior secured loans, the company also invests in subordinated loans and preferred equity, it also makes common equity investments.